---
schema_version: "secwatch.filing_event.v1"
accession: "0001437402-26-000003"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:11:51.087800+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ardelyx reports preliminary Q4 2025 IBSRELA sales ~$87M, XPHOZAH ~$28M; cash $265M

## Summary
- Preliminary unaudited U.S. net product sales: IBSRELA ~$87M Q4, ~$274M FY 2025.
- Preliminary unaudited U.S. net product sales: XPHOZAH ~$28M Q4, ~$104M FY 2025.
- Cash, cash equivalents and short-term investments ~$265M as of Dec 31, 2025, unaudited.
- All figures are preliminary and subject to adjustment upon final audited results.

## SEC filing metadata
- accession: 0001437402-26-000003
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000143740226000003/0001437402-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000143740226000003/ardx-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437402-26-000003
- JSON: https://secwatch.observer/filing/0001437402-26-000003.json
- Plain text: https://secwatch.observer/filing/0001437402-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.